Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ADAPT Study
NCT06462547Phase 2Terminated
- Sponsor
- Inozyme Pharma
- Start
- Jun 2024
- Primary completion
- Sep 2026
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of INZ-701 in ENPP1 deficiency and pseudoxanthoma elasticum (PXE), sponsored by Inozyme Pharma. Primary endpoints: Number of Treatment Emergent Adverse Events at 6 years and Incidence of Anti-Drug Antibodies at 6 years. Started Jun 2024; status: terminated.
02
Drugs
INZ-701
03
Conditions
ENPP1 deficiencypseudoxanthoma elasticum (PXE)
Beyond the preview
Go deeper on NCT06462547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462547.